Resumen de: AU2022221496A1

218015-0024U Disclosed in a method of treating a myeloid neoplasm, acute leukemia, or infectious disease in a subject, the method including administering to a subject in need thereof a pegylated interferon-a at a regular interval of every 2 to 8 weeks at a first dose of 250 to 500 pg.

Resumen de: US2023080834A1

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Resumen de: CA3130929A1

Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance Analysis (DSER), a method developed to identify molecular targets for improved therapy by direct comparison of genomic features of eradicated and resistant subclones in pre- and post-treatment samples from a patient with BRCA2-deficient metastatic prostate cancer. FANCI and EYA4 were identified as candidate DNA repair-related targets for converting subclones from resistant to eradicable, and RNAi-mediated depletion of FANCI confirmed it as a potential target. The EYA4 alteration was associated with adjacent L1 transposon insertion during cancer evolution upon treatment, raising questions surrounding the role of therapy in L1 activation. Both carboplatin and enzalutamide turned on L1 transposon machinery in LNCaP and VCaP but not in PC-3 and 22Rv1 prostate cancer cell lines. L1 activation in LNCaP and VCaP was inhibited by the antiretroviral drug azidothymidine. L1 activation was also detected post-castration in LuCaP 77 and LuCaP 105 xenograft models and post-chemotherapy in previously published time-series transcriptomic data from SCC25 head and neck cancer cells. In conclusion DSER provides an informative intermediate step toward effective precision cancer medicine and should be tested in future studies, especially those including dramatic but temporary metastatic tumor regression. L1 transpo

Resumen de: AU2021314401A1

The present application relates to a sulfur-containing isoindoline derivative, and a preparation method therefor and medical use thereof. In particular, the present application relates to a sulfur-containing isoindoline derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and use thereof as a therapeutic agent, particularly use thereof as a Cereblon modulator in the field of treatment of multiple myeloma.

Resumen de: AU2021322052A1

Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, non-Hodgkin lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative pathologies. Preferred compounds are e.g. 2-(4-((5-(benzo[b]thiophen-3-yl)-1H- tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.

Resumen de: AU2021329899A1

Provided herein is technology for cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of non-Hodgkin lymphoma (NHL) and NHL subtypes (e.g., diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, peripheral T-cell lymphoma).

Resumen de: US2023072300A1

This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.

Resumen de: US2023071910A1

Provided herein are methods of administering a dose of T cells for treating subjects with indolent non-Hodgkin3 s lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. The cells express a recombinant receptor such as a chimeric antigen receptor (CAR) for targeting an antigen of the lymphoma, such as CD19. In some embodiments, the methods are for treating grade 1-3 A follicular lymphoma (FL 1-3 A) or marginal zone lymphoma (MZL), including in heavily pretreated or poor-prognosis subjects, such as subjects that have relapsed after treatment with, or are refractory to treatment with, one or more prior therapies.

Resumen de: US2023072933A1

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Resumen de: US2023073499A1

The present invention belongs to the field of cancer therapy and relates to a composition or product comprising at least one retinoid compound, at least one arsenic compound and at least one proteasome inhibitor, for use in the treatment of acute myeloid leukemia (AML) where the tumor cells are positive for the FLT3-ITD mutation.

Resumen de: US2023076866A1

The present application discloses a human T-lymphoblastic leukemia/lymphoma cell strain named as ZYXY-T1, and its construction method and use thereof. It was conserved in China Center for Type Culture Collection (Wuhan, China) on Jan. 20, 2021, and the preservation number was CCTCC NO: C202143. The present application is obtained by separating mononuclear cells from peripheral blood of one ETP-ALL patient, and culturing the cells in vitro for continuous natural passage. The strain has the typical surface antigen expression characteristics of ETP-ALL, that is, it does not express CD1α, CD5 or CD8, and highly expresses a stem cell marker CD34, and has good proliferation ability in vitro and tumorigenesis ability in vivo; it can be used as a cell material to study the occurrence and development mechanism of ETP-ALL, and can also be used to screen and evaluate ETP-ALL drugs to guide clinical medication.

Resumen de: US2023073558A1

Aspects of the disclosure relate to compositions and methods for predicting prognosis and classifying risk of subjects having certain cancers, for example acute myeloid leukemia (AML). In some embodiments, methods described by the disclosure comprise a step of assessing the mRNA expression of certain leukemic stem cell (LSC)-enriched genes in a subject to produce a predictive score for pediatric AML. In some embodiments, methods described by the disclosure comprise a step of assessing the mRNA expression of certain genes of pharmacological relevance for standard chemotherapy consisting of Cytarabine (also known as Ara-C), daunorubicin and etoposide in a subject to produce a predictive score for pediatric AML.

Resumen de: WO2023030437A1

The present disclosure provides a use of a PI3K inhibitor and a BTK inhibitor in the preparation of a drug for treating lymphoma. Specifically, in the present disclosure, P13K inhibitor is selected from a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a BTK inhibitor is selected from a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.

Resumen de: WO2023029833A1

An SOS1 inhibitor, and a preparation method therefor and the use thereof. The SOS1 inhibitor has a structural formula as represented by formula (I), wherein the symbols and variables are as defined in the description. The SOS1 inhibitor has an SOS1 inhibitory activity and can be used for treating diseases, such as head and neck cancer, lung cancer, mediastinal tumors, gastrointestinal tumors, prostate cancer, testicular cancer, gynecological tumor, breast cancer, kidney and bladder cancer, endocrine system tumor, soft tissue sarcoma, osteosarcoma, rhabdoid tumors, mesothelioma, skin cancer, peripheral nervous system tumors, central nervous system tumors, lymphoma, leukemia, unknown primary cancer, Noonan syndrome, cardiofaciocutaneous syndrome, hereditary gingival fibromatosis and related syndromes thereof.

Resumen de: WO2023033638A1

The present invention relates to an indole alkaloid, specifically the alkaloid (33,3aR,8aS)-3-butyl-5-hydroxy-3,3a,8a-trimethyl-3,3a,8,8a-tetrahydro-2H-furo[2,3-b] indole-2-one, with the generic name Andranone, as an antineoplastic agent against neoplastic cells of colon cancer, breast cancer, leukaemia, central nervous system cancer, prostate cancer, lung cancer and cervical cancer.

Resumen de: WO2023034803A1

Described herein are methods and compositions for use in treating fibrosis by inhibiting Leukemia Inhibitory Factor (LIF) and its receptor (LIFR).

Resumen de: WO2023030299A1

The present invention relates to the use of an EZH2 inhibitor in the preparation of a drug for treating T-cell lymphoma. Specifically, the present invention relates to the use of a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating T-cell lymphoma.

Resumen de: US2023074759A1

The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I)or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.

Resumen de: US2023086030A1

Disclosed are a lymphoma cell-specific drug delivery system for the prevention or treatment of lymphoma and a production method therefor. The lymphoma cell-specific drug delivery system may be delivered into lymphoma cells in an improved manner compared to conventional single-target drug delivery systems, and is applicable to the delivery of various therapeutic drugs for the treatment of lymphoma through the application of a wide range of drugs and the same antibody functionalization strategy on the surface of different types of nanoparticles. In addition, the drug delivery system may be introduced into lymphoma as well as other cancer types by adjusting the type and mixing ratio of antibody, and may propose a method of introducing polymeric nucleic acid drugs having superior physiological stability and drug efficacy compared to conventional monomeric nucleic acid drugs, thereby enabling effective drug treatment of lymphoma which is highly resistant to intracellular drug delivery.

Resumen de: KR20230032829A

본 발명은 비호지킨 림프종 세포 특이적 약물 전달을 위한 항체기능화 나노입자 및 이의 제조방법에 관한 것으로, 본 발명의 비호지킨 림프종 세포 특이적 약물 전달을 위한 항체기능화 나노입자는 기존의 단일 표적 약물전달체보다 개선된 비림프종 세포 내 전달이 가능하고, 광범위한 약물의 적용 및 다른 종류의 나노입자 표면에도 동일한 항체기능화를 통해 비호지킨 림프종의 치료를 위한 다양한 치료제 전달에 적용 가능하다. 또한 항체의 종류 및 배합비를 조정함으로써 림프종뿐만 아니라 다른 암 종에 도입이 가능하며, 기존 단량체 핵산약물에 비하여 생리학적 안정성과 약물 효능이 우수한 폴리머화된 핵산약물 도입 방안을 제시하여, 세포 내 약물전달 저항성이 높은 비호지킨 림프종의 효과적인 약물치료를 가능하게 할 수 있다.

Resumen de: WO2015195848A1

he present invention relates to methods of treating cancer by administering an EZH2 inhibitor or a pharmaceutical composition thereof to the subject in need thereof. The present claims define methods for treating specific subtypes of non-Hodgkin's lymphoma comprising the administration to a subject of EZH2 inhibitors. Preferred EZH2 inhibitors include tazemetostat (EPZ-6438 E7438) and other compounds. Dosage amounts and regimes are also defined.

Resumen de: AU2023200435A1

CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4 phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Resumen de: AU2021369508A1

Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.